Lyra Therapeutics (LYRA) Common Equity (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Common Equity of -$10.7 million in Q4 2025, down 147.62% on a QoQ basis from -$4.3 million in Q3 2025, and down 192.44% YoY from $11.6 million in Q4 2024.
Lyra Therapeutics (LYRA) Common Equity (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Common Equity for 7 consecutive years, with -$10.7 million the latest figure, recorded in Q4 2025.
- Common Equity for Q4 2025 came in at -$10.7 million, down 192.44% year-over-year; the trailing twelve-month figure through Dec 2025 was -$10.7 million (down 192.44% YoY), and the FY2025 annual result was -$10.7 million, down 192.44% from the prior year.
- Common Equity for Q4 2025 stood at -$10.7 million, down from -$4.3 million in the prior quarter.
- The five-year high for Common Equity was $106.2 million in Q2 2022, with the low at -$10.7 million in Q4 2025.
- A 5-year average of $49.0 million and a median of $52.3 million in 2021 frame the typical range for Common Equity.
- Across the five-year window, Common Equity soared 184.18% in 2023 and plunged 192.44% in 2025, its largest moves.
- Lyra Therapeutics' Common Equity stood at $34.3 million in 2021, then soared by 135.32% to $80.8 million in 2022, then gained by 10.73% to $89.4 million in 2023, then tumbled by 87.03% to $11.6 million in 2024, then sank by 192.44% to -$10.7 million in 2025.
- The last three Common Equity figures came in at -$10.7 million (Q4 2025), -$4.3 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -10.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.72 Mn |
| Sep 30, 2025 | -4.33 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 3.87 Mn |
| Dec 31, 2024 | 11.59 Mn |
| Sep 30, 2024 | 20.62 Mn |
| Jun 30, 2024 | 30.98 Mn |
| Mar 31, 2024 | 77.50 Mn |
| Dec 31, 2023 | 89.42 Mn |
| Sep 30, 2023 | 84.24 Mn |
| Jun 30, 2023 | 98.58 Mn |
| Mar 31, 2023 | 66.09 Mn |
| Dec 31, 2022 | 80.75 Mn |
| Sep 30, 2022 | 93.22 Mn |
| Jun 30, 2022 | 106.25 Mn |
| Mar 31, 2022 | 23.26 Mn |
| Dec 31, 2021 | 34.32 Mn |
| Sep 30, 2021 | 47.19 Mn |
| Jun 30, 2021 | 57.50 Mn |
| Mar 31, 2021 | 67.55 Mn |